<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><link rel="stylesheet" href="/css/isb.css" /><title>ProteomeXchange Dataset PXD005536</title>
</head><body bgcolor="#f4f6f8" marginwidth="0" marginheight="0">	<table width="100%" height="127" background="/images/topbackground.jpg" style="box-shadow: 0 6px 8px 0 rgba(0,0,0,0.3);">	<tr align="center"><td><a href="http://www.proteomexchange.org/" border="0"><img src="/images/proteomexchange.png"></a></td><td><a href="http://proteomecentral.proteomexchange.org/" border="0"><img src="/images/proteomecentral.png"></a></td></tr>	</table>		<!-- Main content area here --><!-- BEGIN main content -->

	 <link rel='stylesheet' id='style-css'  href='../javascript/css/patchwork.css' type='text/css' media='all' />
         <script type="text/javascript" src="/javascript/js/toggle.js"></script>
      
       <div id="main">
       <a class="linkback" href="http://proteomecentral.proteomexchange.org/cgi/GetDataset"> &lt;&lt;&lt; Full experiment listing </a>
       <div id="dataset-primary" class="site-content">
       <h1 class="dataset-title">PXD005536</h1>
    
	<div class="dataset-content">
	PXD005536 is an <b>original dataset</b> announced via ProteomeXchange.<BR><BR><div class='dataset-secthead'>Dataset Summary</div>
<table class='dataset-summary'><tr><td><b>Title</b></td><td>Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib</td></tr><tr><td><b>Description</b></td><td class='breakwords'>Acquired drug resistance and tumour relapse impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapeutic strategies to overcome drug resistance represents a significant unmet need. Understanding the signalling pathways that drive drug resistance will facilitate the development of new salvage therapies to effectively treat patients with secondary TKI resistance. In this study, we utilise quantitative mass spectrometry to characterise the global phosphoproteomic alterations that accompany the acquisition of resistance to two FDA-approved multi-target TKIs, pazopanib and dasatinib, in the A204 rhabdoid tumour cell line. Our analysis finds that only a limited fraction of the quantified phosphoproteome (<10%) is altered upon the acquisition of drug resistance with pazopanib resistant cells displaying elevated phosphorylation levels in cytoskeletal regulatory pathways and dasatinib resistant cells showing an upregulation of components of the insulin receptor/IGF1-R signalling pathway. Drug response profiling with a targeted panel of small molecule inhibitors rediscovers several previously reported vulnerabilities associated with pazopanib and dasatinib resistance and identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922. This study provides a useful resource detailing the candidate signalling determinants of acquired TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means of salvage therapy to overcome pazopanib and dasatinib resistance.</td></tr><tr><td><b>HostingRepository</b></td><td>PRIDE</td></tr><tr><td><b>AnnounceDate</b></td><td>2017-08-30</td></tr>
                <tr><td><b>AnnouncementXML</b></td><td><a href='GetDataset?ID=PXD005536-1&outputMode=XML&test=no' target="_blank">Submission_2017-08-30_00:55:57.xml</a></td></tr>
                <tr><td><b>DigitalObjectIdentifier</b></td><td><a href="" target="_blank"></a></td></tr><tr><td><b>ReviewLevel</b></td><td>Peer-reviewed dataset</td></tr><tr><td><b>DatasetOrigin</b></td><td>Original dataset</td></tr><tr><td><b>RepositorySupport</b></td><td>Unsupported dataset by repository</td></tr><tr><td><b>PrimarySubmitter</b></td><td>Frank McCarthy</td></tr><tr><td><b>SpeciesList</b></td><td> scientific name: Homo sapiens (Human);  NCBI TaxID: 9606; </td></tr><tr><td><b>ModificationList</b></td><td>phosphorylated residue</td></tr><tr><td><b>Instrument</b></td><td>LTQ Orbitrap Velos; Q Exactive</td></tr></table>
<div class='dataset-secthead'>Dataset History</div>
<table class="dataset-summary">
<tr><th>Revision</th><th>Datetime</th><th>Status</th><th>ChangeLog Entry</th></tr>
<tr><td >0</td><td >2016-12-09 07:04:10</td><td >ID requested</td><td ></td></tr>
<tr><td class="dataset-currentrev"><a href="GetDataset?ID=PXD005536-1&test=no"><span class='current'>&#9205;</span> 1</a></td><td class="dataset-currentrev">2017-08-30 00:55:58</td><td class="dataset-currentrev">announced</td><td class="dataset-currentrev"></td></tr>
</table>
<div class='dataset-secthead'>Publication List </div>
<table class='dataset-summary'>
<tr><td>Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH, Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J Proteomics, 170():130-140(2018) [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=28842319" target="_blank">pubmed</a>]</td></tr></table>
<div class='dataset-secthead'>Keyword List </div>
<table class='dataset-summary'>
<tr><td>submitter keyword: A204, phosphoproteomics, pazopanib, dasatinib, resistance</td></tr></table>
<div class='dataset-secthead'>Contact List </div>
<table class='dataset-summary'>
<tr><th colspan='2'>Paul Huang</th></tr>
<tr><td>contact affiliation</td><td>Protein Networks, The Institute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London, SW3 6JB, UK</td></tr><tr><td>contact email</td><td>paul.huang@icr.ac.uk</td></tr><tr><td>lab head</td><td></td></tr><tr><th colspan='2'>Frank McCarthy</th></tr>
<tr><td>contact affiliation</td><td>ICR</td></tr><tr><td>contact email</td><td>frank.mccarthy@icr.ac.uk</td></tr><tr><td>dataset submitter</td><td></td></tr></table>
<div class='dataset-secthead'>Full Dataset Link List </div>
<table class='dataset-summary'>
<tr><td><a href=ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2017/08/PXD005536 target="_blank">Dataset FTP location</a></td></tr><tr><td><a href=http://www.ebi.ac.uk/pride/archive/projects/PXD005536 target="_blank">PRIDE project URI</a></td></tr></table>

		 <div class='dataset-secthead'>Repository Record List </div>
                 <div id="less" onclick='toggle("less","more","repositoryRecordList")' title='Expand Record List'>[ + ]</div>
		 <div id="more" onclick='toggle("more","less","repositoryRecordList")' title='Hide Record List' style='display: none'>[ - ]</div>
		 <ul id="repositoryRecordList" style='display: none'>
        <li>PRIDE<ol><li><a href="http://www.ebi.ac.uk/pride/archive/projects/PXD005536" target="_blank">PXD005536</a><ol><li>Label: PRIDE project</li><li>Name: Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib</li></ol></li></li></ul>

      
	 </div><!-- #content -->
	 </div><!-- #primary .site-content -->
	 </div><!-- #main -->
      <!-- END main content -->	<!-- Begin Footer -->	<br clear="all">	<div class="footer">	<table width="100%"><tr>	<td style="vertical-align:top; text-align:left; padding: 10px;">If you have a question or comment about ProteomeXchange, please <a href="http://www.proteomexchange.org/contact">contact us</a>!<BR>	<a href="http://www.proteomexchange.org/subscribe/index.html"><img width="70" height="20" src="/images/subscribe_button-small.jpg"><font size="+1" color="#aa0000"> to receive all new ProteomeXchange dataset release announcements!</font></a>	</td>	<td style="text-align:right; padding: 10px;">	<a class="logolink" target="_blank" href="http://www.ebi.ac.uk/"><img src="/images/ebi_footer_logo.png"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://www.isbscience.org/"><img src="/images/isb.jpg"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://ec.europa.eu/research/fp7/index_en.cfm"><img src="/images/capacities.png"></a>	</td></tr></table>	</div>				</body></html>